226-240 of 847
Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
NeuroFrontiersMetabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
Pavan Barghava, MD
Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events
NeuroFrontiersSafety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events
Amber Salter, PhD
MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse
NeuroFrontiersMS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse
Michael Kornberg, MD, PhD
Managing Multiple Sclerosis: The Impact of Dietary Modifications
On the Frontlines of Multiple SclerosisManaging Multiple Sclerosis: The Impact of Dietary Modifications
Charles Turck, PharmD, BCPS, BCCCP
Anna A. Shah, MD
Strategies and Considerations for Managing MS in Pregnant Women
On the Frontlines of Multiple SclerosisStrategies and Considerations for Managing MS in Pregnant Women
Charles Turck, PharmD, BCPS, BCCCP
Anna A. Shah, MD
Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
NeuroFrontiersCognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
Christopher Lock, MD
- advertisement
Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD
NeuroFrontiersUnderstanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD
Dalia Rotstein, MD, MPH
Emerging Technologies in MS: Neuromodulation and Myelin Regeneration
NeuroFrontiersEmerging Technologies in MS: Neuromodulation and Myelin Regeneration
Cristin Welle, PhD
MS and Structural Disconnectivity: Pathophysiology and Emerging Technologies
NeuroFrontiersMS and Structural Disconnectivity: Pathophysiology and Emerging Technologies
Amy Kuceyeski, PhD
Multiple Sclerosis Explained: Understanding Its Epidemiology
NeuroFrontiersMultiple Sclerosis Explained: Understanding Its Epidemiology
Jonathan E. Howard, MD
Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects
NeuroFrontiersGeneralized Myasthenia Gravis Management: Evaluating Long-Term Effects
Maxwell H. Levy, MD
Social Support in Schizophrenia: The Role of Emotional Awareness and Regulation
NeuroFrontiersSocial Support in Schizophrenia: The Role of Emotional Awareness and Regulation
David Kimhy, PhD
- advertisement
Uncovering Disparities in Teleneurology Utilization Post-Pandemic
On the Frontlines of Multiple SclerosisUncovering Disparities in Teleneurology Utilization Post-Pandemic
Marisa McGinley, DO
Genetics and Schizophrenia: Key Ethical Considerations
NeuroFrontiersGenetics and Schizophrenia: Key Ethical Considerations
Aaron Besterman, MD
Recognizing Multiple Sclerosis Awareness Month: Ways to Make an Impact
NeuroFrontiersRecognizing Multiple Sclerosis Awareness Month: Ways to Make an Impact
